Abstract
The microtubule-targeting agents have made significant contributions to cancer therapy over the past 50 years. The vinca alkaloids and taxanes have been used to treat a broad range of malignancies, including leukemias and lymphomas and many types of solid tumors. The taxanes have been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and they are increasingly being used in early stage disease. This chapter reviews the pharmacology, clinical indications, and toxicities associated with the vinca alkaloids and taxanes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Noble, R., Beer, C. T., and Cutts, J. H. (1958) Role of change observations in chemotherapy: Vinca rosea. Ann. N.Y. Acad. Sci. 76, 882ā894.
Karon, M., Freireich, E. J., and Frei, E. I. (1962) A preliminary report on vincristine sulfate; a new active agent for the treatment of acute leukemia. Pediatrics 30, 791ā802.
Costa, G., Hreshchyshyn, M. M., and Holland, J. F. (1962) Initial clinical studies with vincristine. Cancer Chemother. Rep. 24, 39ā44.
Donoso, J. A., Haskins, K. M., and Himes, R. H. (1979) Effect of microtubule-associated proteins on the interaction of vincristine with microtubules and tubulin. Cancer Res. 39, 1604ā1610.
George, P., Journey, L. J., and Goldstein, M. N. (1965) Effect of vincristine on the fine structure of HeLa cells during mitosis. J. Natl. Cancer Inst. 35, 355ā375.
Himes, R. H., Kersey, R. N., Heller-Bettinger, I., and Samson, F. E. (1976) Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 36, 3798ā3802.
Jordan, M. A., Thrower, D., and Wilson, L. (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51, 2212ā2222.
Owellen, R. J., Hartke, C. A., Dickerson, R. M., and Hains, F. O. (1976) Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 36, 1499ā1502.
Rahmani, R. and Zhou, X. J. (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 17, 269ā281.
Owellen, R. J., Root, M. A., and Hains, F. O. (1977) Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 37, 2603ā2607.
Sethi, V. S., Jackson, D. V., Jr., White, D. R., et al. (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 41, 3551ā3555.
Sethi, V. S. and Kimball, J. C. (1981) Pharmacokinetics of vincristine sulfate in children. Cancer Chemother. Pharmacol. 6, 111ā115.
Bender, R. A., Castle, M. C., Margileth, D. A., and Oliverio, V. T. (1977) The pharmacokinetics of [3H]-vincristine in man. Clin. Pharmacol. Ther. 22, 430ā435.
Zhou-Pan, X. R., Seree, E., Zhou, X. J., et al. (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 53, 5121ā5126.
Zhou, X. J., Zhou-Pan, X. R., Gauthier, T., Placidi, M., Maurel, P., and Rahmani, R. (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem. Pharmacol. 45, 853ā861.
El Dareer, S. M., White, V. M., Chen, F. P., Mellet, L. B., and Hill, D. L. (1977) Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys. Cancer Treat. Rep. 61, 1269ā1277.
Jackson, D. V., Jr., Castle, M. C., and Bender, R. A. (1978) Biliary excretion of vincristine. Clin. Pharmacol. Ther. 24, 101ā107.
Rosenthal, S. and Kaufman, S. (1974) Vincristine neurotoxicity. Ann. Intern. Med. 80, 733ā737.
Sandler, S. G., Tobin, W., and Henderson, E. S. (1969) Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19, 367ā374.
Van den Berg, H. W., Desai, Z. R., Wilson, R., Kennedy, G., Bridges, J. M., and Shanks, R. G. (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother. Pharmacol. 8, 215ā219.
Owellen, R. J. and Hartke, C. A. (1975) The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. Cancer Res. 35, 975ā980.
Owellen, R. J., Hartke, C. A., and Hains, F. O. (1977) Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 37, 2597ā2602.
Marquet, P., Lachatre, G., Debord, J., Eichler, B., Bonnaud, F., and Nicot, G. (1992) Pharmacokinetics of vinorelbine in man. Eur. J. Clin. Pharmacol. 42, 545ā547.
Leveque, D., Jehl, F., Quoix, E., and Breillout, F. (1992) Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J. Clin. Pharmacol. 32, 1096ā1098.
Bore, P., Rahmani, R., van Cantfort, J., Focan, C., and Cano, J. P. (1989) Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother. Pharmacol. 23, 247ā251.
Mathe, G. and Reizenstein, P. (1985) Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett. 27, 285ā293.
Khayat, D., Rixe, O., Brunet, R., et al. (2004) Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother. Pharmacol. 54, 193ā205.
Gidding, C. E., Kellie, S. J., Kamps, W. A., and de Graaf, S. S. (1999) Vincristine revisited. Crit. Rev. Oncol. Hematol. 29, 267ā287.
Rowinsky, E. K. and Donehower, R. C. (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52, 35ā84.
Lampert, F. and Henze, G. (1997) Acute lymphoblastic leukaemia, in Pediatric Oncology: Clinical Practice and Controversies, (Pinkerton, C. and Plowman, P. N., ed.), Chapman & Hall Medical, London, UK, pp. 258ā278.
Patte, C. (1997) Childhood non-Hodgkinās lymphoma, in Pediatric Oncology: Clinical Practice and Controversies, (Pinkerton, C. and Plowman, P. N., ed.), Chapman & Hall Medical, London, UK, pp. 278ā291.
Oberlin, O. and McDowell, H. P. (1997) Hodgkinās disease, in Pediatric Oncology: Clinical Practice and Controversies, (Pinkerton, C. and Plowman, P. N., ed.), Chapman & Hall Medical, London, UK, pp. 296ā316.
DāAngio, G. J., Evans, A. E., Breslow, N., et al. (1976) The treatment of Wilmsā tumor: Results of the national Wilmsā tumor study. Cancer 38, 633ā646.
Ninane, J. and Pearson, A. D. J. (1997) Neuroblastoma, in Pediatric Oncology: Clinical Practice and Controversies, (Pinkerton, C. and Plowman, P. N., ed.), Chapman & Hall Medical, London, UK, pp. 443ā446.
Wexler, L. and Helman, L. J. (1997) Rhabdomyosarcoma and the undifferentiated sarcomas, in Principles and Practice of Pediatric Oncology, (Pizzo, P. and Poplack, D. G., ed.), Lippincott-Raven, Philadelphia, PA, pp. 799ā830.
Horowitz, M., Malawer, M. M., and Woo, S. Y. (1997) Hicks JM Ewingās sarcoma family of tumors: Ewingās neuroectodermal tumors, in Principles and Practice of Pediatric Oncology, (Pizzo, P. and Poplack, D. G., ed.), Lippincott-Raven, Philadelphia, PA, pp. 831ā863.
Armitage, J., Mauch, P. M., Harris, N. L., and Bierman, P. (2001) Non-Hodgkinās lymphomas, in Cancer: Principles and Practice of Oncology, (DeVita, Jr, V. T., Hellman, S., and Rosenberg, S. A., ed.), Lippincott Williams & Wilkins, Philadelphia, PA, pp. 2256ā2315.
Diehl, V., Mauch, P. M., and Harris, N. L. (2001) Hodgkinās Disease, in Cancer: Principles and Practice of Oncology, (DeVita, Jr, V. T., Hellman, S., and Rosenberg, S. A., ed.), Lippincott Williams & Wilkins, Philadelphia, PA, pp. 2339ā2388.
DeVita, V., Serpick, A. A., and Carbone, P. P. (1970) Combination chemotherapy in the treatment of advanced Hodgkinās disease. Ann. Intern. Med. 73, 891ā895.
Longo, D. L., Young, R. C., Wesley, M., et al. (1986) Twenty years of MOPP therapy for Hodgkinās disease. J. Clin. Oncol. 4, 1295ā1306.
Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., and Rosenberg, S. A. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkinās disease: mature results of a prospective clinical trial. J. Clin. Oncol. 20, 630ā637.
Kantarjian, H. M., OāBrien, S., Smith, T. L., et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18, 547ā561.
Samson, D., Gaminara, E., Newland, A., et al. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2, 882ā885.
Kaplan, L., Abrams, D., and Volberding, P. (1986) Treatment of Kaposiās sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat. Rep. 70, 1121ā1122.
Gill, P., Rarick, M., Bernstein-Singer, M., et al. (1990) Treatment of advanced Kaposiās sarcoma using a combination of bleomycin and vincristine. Am. J. Clin. Oncol. 13, 315ā319.
Livingston, R. and Carter, S. K. (1970) Single Agents in Cancer Chemotherapy, IFI/Plenum, New York.
Santoro, A. and Bonadonna, G. (1979) Prolonged disease-free survival in MOPP-resistant Hodgkinās disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother. Pharmacol. 2, 101ā105.
Papa, G., Mandelli, F., Anselmo, A. P., et al. (1982) Treatment of MOPP-resistant Hodgkinās disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Eur. J. Cancer Clin. Oncol. 18, 803ā806.
Carbone, P. P., Spurr, C., Schneiderman, M., Scotto, J., Holland, J. F., and Shnider, B. (1968) Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 28, 811ā822.
Stutzman, L., Ezdinli, E. Z., and Stutzman, M. A. (1966) Vinblastine sulfate vs cyclophosphamide in the therapy for lymphoma. JAMA 195, 173ā178.
Jackson, D. V., Jr., Spurr, C. L., Caponera, M. E., et al. (1987) Vinblastine infusion in non-Hodgkinās lymphomas: lack of total cross-resistance with vincristine. Cancer Invest. 5, 535ā539.
Sternberg, C. N., Yagoda, A., Scher, H. I., et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64, 2448ā2458.
Sternberg, C. N., Yagoda, A., Scher, H. I., et al. (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139, 461ā469.
Grossman, H. B., Natale, R. B., Tangen, C. M., et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859ā866.
Epstein, J. B. and Scully, C. (1989) Intralesional vinblastine for oral Kaposi sarcoma in HIV infection. Lancet 2, 1100ā1101.
Gill, P. S., Akil, B., Colletti, P., et al. (1989) Pulmonary Kaposiās sarcoma: clinical findings and results of therapy. Am. J. Med. 87, 57ā61.
Gregory, R. K. and Smith, I. E. (2000) Vinorelbine: a clinical review. Br. J. Cancer 82, 1907ā1913.
The Elderly Lung Cancer Vinorelbine Italian Study Group. (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall-cell lung cancer. J. Natl. Cancer Inst. 91, 66ā72.
Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., et al. (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 16, 2459ā2465.
Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J. P., and Vansteenkiste, J. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351ā360.
Fumoleau, P., Delgado, F. M., Delozier, T., et al. (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. 11, 1245ā1252.
Burstein, H. J., Harris, L. N., Marcom, P. K., et al. (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 21, 2889ā2895.
Casey, E. B., Jellife, A. M., Le Quesne, P. M., and Millett, Y. L. (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96, 69ā86.
Bradley, W. G., Lassman, L. P., Pearce, G. W., and Walton, J. N. (1970) The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J. Neurol. Sci. 10, 107ā131.
Weiss, H. D., Walker, M. D., and Wiernik, P. H. (1974) Neurotoxicity of commonly used antineoplastic agents (first of two parts). N. Engl. J. Med. 291, 75ā81.
Slyter, H., Liwnicz, B., Herrick, M. K., and Mason, R. (1980) Fatal myeloencephalopathy caused by intrathecal vincristine. Neurology 30, 867ā871.
Steurer, G., Kuzmits, R., Pavelka, M., Sinzinger, H., Fritz, E., and Ludwig, H. (1989) Early-onset thrombocytopenia during combination chemotherapy in testicular cancer is induced by vinblastine. Cancer 63, 51ā58.
Gottlieb, R. J. and Cuttner, J. (1971) Vincristine-induced bladder atony. Cancer 28, 674ā675.
Hansen, S. W. (1990) Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 300, 511ā512.
Bostrom, B. (1988) Severe ileus from cisplatin and vinblastine infusion in neuroblastoma. J. Clin. Oncol. 6, 1356.
Cvitkovic, E. and Izzo, J. (1992) The current and future place of vinorelbine in cancer therapy. Drugs 44, 36ā45.
Lapeyre-Mestre, M., Gregoire, N., Bugat, R., and Montastruc, J. L. (2004) Vinorelbine-related cardiac events: a meta-analysis of randomized clinical trials. Fundam Clin. Pharmacol. 18, 97ā105.
Besenval, M., Delgado, M., Demarez, J. P., and Krikorian, A. (1989) Safety and tolerance of Navelbine in phase IāII clinical studies. Semin. Oncol. 16, 37ā40.
Rowinsky, E. K., Onetto, N., Canetta, R. M., and Arbuck, S. G. (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19, 646ā662.
Bissery, M. C., Nohynek, G., Sanderink, G. J., and Lavelle, F. (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6, 339ā368.
Schiff, P. B., Fant, J., and Horwitz, S. B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277, 665ā667.
Kumar, N. (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 256, 10,435ā10,441.
Manfredi, J. J. and Horwitz, S. B. (1984) Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25, 83ā125.
Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816ā825.
Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. (1993) Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr. 55ā61.
Dumontet, C., Duran, G. E., Steger, K. A., Beketic-Oreskovic, L., and Sikic, B. I. (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 56, 1091ā1097.
Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48, 4093ā4100.
Giannakakou, P., Sackett, D. L., Kang, Y. K., et al. (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272, 17,118ā17,125.
Rowinsky, E. K., Burke, P. J., Karp, J. E., Tucker, R. W., Ettinger, D. S., and Donehower, R. C. (1989) Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 49, 4640ā4647.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., and Paietta, E. (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47, 2486ā2493.
Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., and Dutcher, J. P. (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 5, 1232ā1239.
Grem, J. L., Tutsch, K. D., Simon, K. J., et al. (1987) Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat. Rep. 71, 1179ā1184.
Donehower, R. C., Rowinsky, E. K., Grochow, L. B., Longnecker, S. M., and Ettinger, D. S. (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71, 1171ā1177.
Rowinsky, E. K. (1995) Phamacology and metabolism, in Paclitaxel in Cancer Treatment, (McGuire, W. and Rowinsky, E. K., ed.), Dekker, New York, pp. 91ā120.
Monsarrat, B., Mariel, E., Cros, S., et al. (1990) Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab. Dispos. 18, 895ā901.
Rowinsky, E. K. and Donehower, R. C. (1995) Paclitaxel (taxol). N. Engl. J. Med. 332, 1004ā1014.
Marre, F., Sanderink, G. J., de Sousa, G., Gaillard, C., Martinet, M., and Rahmani, R. (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 56, 1296ā1302.
Cortes, J. E. and Pazdur, R. (1995) Docetaxel. J. Clin. Oncol. 13, 2643ā2655.
van Oosterom, A. T., Schrijvers, D., and Schriivers, D. (1995) Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 6, 356ā368.
Kohn, E. C., Sarosy, G., Bicher, A., et al. (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer Inst. 86, 18ā24.
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., and Goldberg, G. L. (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10, 1748ā1753.
Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., and Barrett, R. J. (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12, 1748ā1753.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., et al. (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9, 1692ā1703.
McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1ā6.
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., et al. (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12, 2654ā2666.
Ozols, R. F., Bundy, B. N., Greer, B. E., et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194ā3200.
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18, 3084ā3092.
du Bois, A., Luck, H. J., Meier, W., et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95, 1320ā1329.
Francis, P., Schneider, J., Hann, L., et al. (1994) Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12, 2301ā2308.
Kaye, S. B., Piccart, M., Aapro, M., and Kavanagh, J. (1995) Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur. J. Cancer 31A, S14āS17.
Kavanagh, J. J., Kudelka, A. P., de Leon, C. G., et al. (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. 2, 837ā842.
Piccart, M. J., Gore, M., Ten Bokkel Huinink, W., et al. (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Natl. Cancer Inst. 87, 676ā681.
Vasey, P. A. (2003) Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J. Clin. Oncol. 21, 136ā144.
Niwa, Y., Nakanishi, T., Kuzuya, K., Nawa, A., and Mizutani, S. (2003) Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int. J. Clin. Oncol. 8, 343ā347.
Holmes, F. A., Walters, R. S., Theriault, R. L., et al. (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83, 1797ā1805.
Gianni, L., Munzone, E., Capri, G., et al. (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J. Natl. Cancer Inst. 87, 1169ā1175.
Bishop, J. F., Dewar, J., Toner, G. C., et al. (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. 17, 2355ā2364.
Chevallier, B., Fumoleau, P., Kerbrat, P., et al. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 13, 314ā322.
Dieras, V., Chevallier, B., Kerbrat, P., et al. (1996) A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br. J. Cancer 74, 650ā656.
Hudis, C. A., Seidman, A. D., Crown, J. P., et al. (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 58ā65.
Trudeau, M. E., Eisenhauer, E. A., Higgins, B. P., et al. (1996) Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 14, 422ā428.
Seidman, A., Berry, D., Cirrincione, C., et al. (2004) American Society of Clinical Oncology. New Orleans, LA.
Henderson, I. C., Berry, D. A., Demetri, G. D., et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976ā983.
Martin, M., Pienkowski, T., Mackey, J., et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302ā2313.
Murphy, W. K., Fossella, F. V., Winn, R. J., et al. (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85, 384ā388.
Fossella, F. V., Lee, J. S., Shin, D. M., et al. (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Clin. Oncol. 13, 645ā651.
Fossella, F. V., Lee, J. S., Murphy, W. K., et al. (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 12, 1238ā1244.
Francis, P. A., Rigas, J. R., Kris, M. G., et al. (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 12, 1232ā1237.
Cerny, T., Kaplan, S., Pavlidis, N., et al. (1994) Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer 70, 384ā387.
Kelly, K., Crowley, J., Bunn, P. A., Jr., et al. (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19, 3210ā3218.
Shepherd, F. A., Dancey, J., Ramlau, R., et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095ā2103.
Belani, C. P., Choy, H., Bonomi, P., et al. (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J. Clin. Oncol. 23, 5883ā5891.
Strauss, G., Herndon, J., Maddaus, M. A., et al. (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract). Proc. Am. Soc. Clin. Oncol. 23, 621s.
Smyth, J. F., Smith, I. E., Sessa, C., et al. (1994) Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur. J. Cancer 30A, 1058ā1060.
Rowinsky, E. K. (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48, 353ā374.
Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502ā1512.
Petrylak, D. P., Tangen, C. M., Hussain, M. H., et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513ā1520.
Motzer, R. J., Bajorin, D. F., Schwartz, L. H., et al. (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol. 12, 2277ā2283.
Kondagunta, G. V., Bacik, J., Donadio, A., et al. (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549ā6555.
Roth, B. J., Dreicer, R., Einhorn, L. H., et al. (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264ā2270.
Dimopoulos, M. A., Papadimitriou, C. A., Georgoulias, V., et al. (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol. Oncol. 78, 52ā57.
Hoskins, P. J., Swenerton, K. D., Pike, J. A., et al. (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19, 4048ā4053.
Gill, P. S., Tulpule, A., Espina, B. M., et al. (1999) Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposiās sarcoma. J. Clin. Oncol. 17, 1876ā1883.
Hensley, M. L., Maki, R., Venkatraman, E., et al. (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20, 2824ā2831.
Urba, S. G., Orringer, M. B., Ianettonni, M., Hayman, J. A., and Satoru, H. (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98, 2177ā2183.
El-Rayes, B. F., Shields, A., Zalupski, M., et al. (2004) A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann. Oncol. 15, 960ā965.
Clark, J. I., Hofmeister, C., Choudhury, A., et al. (2001) Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 92, 2334ā2340.
Fountzilas, G., Skarlos, D., Athanassiades, A., et al. (1997) Paclitaxel by threehour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 8, 451ā455.
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G., and Donehower, R. C. (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20, 1ā15.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., et al. (1990) Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263ā1268.
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., and Donehower, R. C. (1993) Neurotoxicity of Taxol. J. Natl. Cancer Inst. Monogr. 15, 107ā115.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., and Donehower, R. C. (1991) Cardiac disturbances during the administration of taxol. J. Clin. Oncol. 9, 1704ā1712.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2007 Humana Press Inc.
About this protocol
Cite this protocol
Zelnak, A.B. (2007). Clinical Pharmacology and Use of Microtubule-Targeting Agents in Cancer Therapy. In: Zhou, J. (eds) Microtubule Protocols. Methods in Molecular Medicineā¢, vol 137. Humana Press. https://doi.org/10.1007/978-1-59745-442-1_15
Download citation
DOI: https://doi.org/10.1007/978-1-59745-442-1_15
Publisher Name: Humana Press
Print ISBN: 978-1-58829-642-9
Online ISBN: 978-1-59745-442-1
eBook Packages: Springer Protocols